Case ReportsSuccessful Palliation of Malignant Ascites From Peritoneal Mesothelioma by Laparoscopic Intraperitoneal Hyperthermic ChemotherapyPatriti, Alberto MD*; Cavazzoni, Emanuel MD*; Graziosi, Luigina MD*; Pisciaroli, Antonio MD*; Luzi, Debora MD†; Gullà, Nino MD*; Donini, Annibale MD*Author Information *Section of General and Emergency Surgery, Department of Surgery †Section of Internal Medicine and Oncological Sciences, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy Reprints: Alberto Patriti, MD, Section of General and Emergency Surgery, Department of Surgery, University of Perugia, Ospedale Santa Maria della Misericordia, San Sisto, Perugia 06156, Italy (e-mail: [email protected]). Received for publication April 8, 2007; accepted January 29, 2008 Surgical Laparoscopy, Endoscopy & Percutaneous Techniques: August 2008 - Volume 18 - Issue 4 - p 426-428 doi: 10.1097/SLE.0b013e318173a61e Buy Metrics Abstract A variety of options have been proposed to treat malignant ascites but most of them have failed to reach a significant impact in terms of palliation. Laparoscopic hyperthermic intraperitoneal chemotherapy (LHIPEC) could represent a good therapeutic tool for patients in whom medical therapies have failed and peritoneovenous shunting is contraindicated. Here we present a case of a 49-year-old woman with malignant ascites secondary to peritoneal spreading of a right pleural mesothelioma. After failure of medical therapy, the patient underwent LHIPEC with Cisplatin 25 mg/m2/L and Doxorubicin 7 mg/m2/L. A dramatic reduction of ascites was documented in the postoperative period and the patient experienced complete abdominal symptom relief. Ascites did not recur during a follow-up period of 6 months. LHIPEC could be a good therapeutic option to palliate malignant ascites from mesothelioma in cases not eligible for a radical treatment. Further studies are needed to standardize dosage and perfusion parameters. © 2008 Lippincott Williams & Wilkins, Inc.